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Background:MMP1 is overexpressed in malignant tumors and its levels are associated with poor prognosis.
Results:Mice deficient in Mmp-1a, the ortholog of human MMP-1, develop fewer lung carcinomas than controls and show a
Th1 anti-inflammatory response.
Conclusion:Mmp-1a is a protumoral protease that alters Th1/Th2 cytokine balance.
Significance:Mmp1a-deficient mice are a new model for the functional analysis of this metalloproteinase in cancer.
Human MMP-1 is a matrix metalloproteinase repeatedly
associatedwithmany pathological conditions, including cancer.
Thus, MMP1 overexpression is a poor prognosis marker in a
variety of advanced cancers, including colorectal, breast, and
lung carcinomas.Moreover,MMP-1plays a key role in themeta-
static behavior of melanoma, breast, and prostate cancer cells.
However, functional andmechanistic studies on the relevanceof
MMP-1 in cancer have been hampered by the absence of an in
vivo model. In this work, we have generated mice deficient in
Mmp1a, the murine ortholog of human MMP1. Mmp1a/
mice are viable and fertile and do not exhibit obvious abnormal-
ities, which has facilitated studies of cancer susceptibility. These
studies have shown a decreased susceptibility to develop lung
carcinomas induced by chemical carcinogens in Mmp1a/
mice. Histopathological analysis indicated that tumors gener-
ated in Mmp1a/ mice are smaller than those of wild-type
mice, consistently with the idea that the absence of Mmp-1a
hampers tumor progression. Proteomic analysis revealed
decreased levels of chitinase-3-like 3 and accumulation of the
receptor for advanced glycation end-products and its ligand
S100A8 in lung samples from Mmp1a/ mice compared with
those from wild-type. These findings suggest that Mmp-1a
could play a role in tumor progression bymodulating the polar-
ization of aTh1/Th2 inflammatory response to chemical carcin-
ogens. On the basis of these results, we propose that Mmp1a
knock-out mice provide an excellent in vivomodel for the func-
tional analysis of humanMMP-1 in bothphysiological andpath-
ological conditions.
The matrix metalloproteinases (MMPs)2 are a family of
structurally related enzymes that can collectively degrade the
main protein components of the extracellular matrix and base-
mentmembranes (1). On the basis of these degrading activities,
MMPs have been considered as essential enzymes in the inva-
sive andmetastatic properties of tumor cells (2). These findings,
together with multiple clinical and experimental data associat-
ing MMPs with tumor progression, stimulated the search for
MMP inhibitors with ability to block the activities of these
enzymes in cancer. However, most clinical trials with synthetic
MMP inhibitors failed to provide appreciable benefits to
patients with advanced cancer (3). These negative results have
forced a profound re-evaluation of the functional and clinical
relevance of MMPs in cancer as well as a reformulation of the
MMP inhibition strategies used in these clinical trials (3, 4). As
a direct consequence of these post-trial studies, new paradigms
have recently emerged in relation to the cancer relevance of the
different members of this complex family of endoproteases.
First, many experimental data have shown that MMPs are not
exclusively implicated in the proteolytic breakdown of tissue
barriers for metastatic spread. Thus, these enzymes may target
a diversity of non-matrix substrates and influence other critical
steps in tumor evolution such as cell proliferation, differentia-
tion, angiogenesis, or apoptosis (5). Additionally, these new
studies have revealed the occurrence ofMMPs such asMMP-8,
MMP-12, and MMP-26, which play a protective role during
tumor progression (6). Furthermore, other MMPs such as
MMP-3, MMP-9, and MMP-19, which were originally recog-
nized as protumorigenic enzymes, may also function as tumor-
suppressive proteases in some specific situations (7–10).
These recent experimental findings have provided some
explanations for the lack of success of clinical trials based on the
use of broad-range MMP inhibitors in patients with advanced
stages of cancer, as they would also reduce the host-protective
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antitumor properties of certain MMPs (3, 4). Likewise, the
administration of these MMP inhibitors to patients with
advanced cancer would be of limited value for those cases in
which MMPs play important roles during early stages of the
disease (3, 4). Accordingly, it is necessary to perform a detailed
analysis of the specific role of each individual MMP in the mul-
tiple stages of tumor evolution. This is the case for fibroblast or
interstitial collagenase (MMP-1), the first member of theMMP
family identified in human tissues and widely associated with
cancer but whose functional relevance in the progression of the
disease is still largely unknown (11, 12).
HumanMMP-1 is produced by a variety of tumor cells aswell
as by adjacent stromal fibroblasts in response to factors derived
from transformed cells. Clinical studies have reported that
MMP-1 is overexpressed in a number ofmalignant tumors, and
its presence is associated with poor prognosis in different can-
cers such as colorectal, breast, and lung carcinomas (13–15).
Moreover, MMP1 has been identified as one of the four key
genes required for lungmetastatic colonization in breast cancer
(16). Additionally, MMP-1 together with ADAMTS-1 proteo-
lytically engage EGF-like growth factors in anosteolytic signaling
cascade, which facilitates bone metastasis (17). Furthermore,
MMP-1 produced in the stromal tumormicroenvironment acti-
vates the proinvasive functions of protease-activated receptor 1
and promotes invasion and tumorigenesis of breast cancer cells
(18). Likewise, experimental manipulation of the expression
levels of this protease alters the metastatic behavior of mela-
noma, breast, and prostate cancer cells (19–21). However,
functional and mechanistic studies on the relevance of MMP-1
in cancer have been hampered by the absence of an in vivo
model ofMMP1 deficiency. To address this question, we have
undertaken studies to generate mutant mice deficient in
Mmp1a, the mouse orthologous gene of humanMMP1 (22). In
this work, we describe the generation ofMmp1a/ mice and
analyze their cancer susceptibility, with the finding that loss of
Mmp1a partially protects mice against development of lung
carcinomas induced by chemical carcinogens. We have also
performed a series of histopathological and proteomic analysis
that have provided information about the mechanisms under-
lyingMmp-1a implication in lung cancer development. Finally,
we propose that Mmp1a/ mice represent a novel in vivo
model to elucidate the functional relevance of human MMP-1
in the context of the large complexity and diversity of proteo-
lytic enzymes.
EXPERIMENTAL PROCEDURES
Animals—To generate Mmp1a/ mice, we first isolated a
genomic PAC clone encoding Mmp1a from a mouse 129/SvJ
library (HGMP Resource Centre) by using a murine Mmp1a
cDNA fragment as a probe. Then, we used the plasmid pKO
scrambler V916 (Lexicon Genetics) to construct the Mmp1a
targeting vector. A 1.4-kb HindIII fragment from the 5-flank-
ing containing part of exon 1, exons 2 and 3, and part of exon 4
was used as the 5-homologous region, whereas a 6.8-kb frag-
ment spanning from exon 6 to exon 7 was used as the 3-region
of homology (see Fig. 1A). The PGK-neo cassette was sub-
cloned into an AscI site of the vector with the transcriptional
orientation opposite to that of Mmp1a and replaced a 1.7-kb
fragment containing exons 4, 5, and part of exon 6 of the gene.
The targeting vector was linearized by digestion with NotI
and electroporated into HM-1 (129/Ola Hsd-Hprtb-m3)
embryonic stemcells. Resistant cloneswere selected for homol-
ogous recombination with G418 and ganciclovir. Southern blot
analysis of 198 neomycin-resistant colonies, using a 5-external
probe revealed homologous recombination in four independ-
ent clones. Correct recombination on the 3-side was verified
by PCR analysis. Two of these heterozygous stem cell clones
were aggregated to CD1 morulas and transferred into uteri of
pseudopregnant females to generate chimeras. Highly chimeric
males were mated with C57BL/6J females, and the offspring
was screened by Southern blot analysis of tail genomic DNA.
Heterozygous mice from the two different clones were inter-
crossed to generate the colony of Mmp1a-deficient mice used
in this study.
Northern Blot Analysis—Total RNAwas isolated from frozen
placenta samples obtained from wild-type and knock-out
female mice at 13.5 days of embryonic development by using a
commercial kit (RNeasy Mini kit; Qiagen). A total of 15 g of
denatured RNA was separated by electrophoresis on 1.2% aga-
rose gels and transferred to Hybond N (Amersham Biosci-
ences). Blots were prehybridized at 42 °C for 3 h in 50% form-
amide, 5 SSPE (1 150 mM NaCl, 10 mM NaH2PO4, 1 mM
EDTA, pH 7.4), 10 Denhardt’s solution, 2% SDS, and 100
g/ml denatured herring sperm DNA, and then hybridized
with a random primed 32P-labeled cDNA probe for mouse
Mmp1a (40090601, Geneservice) for 20 h under the same con-
ditions. Blots were washed with 0.1 SSC, 0.1% SDS for 2 h at
50 °C and exposed to autoradiography. RNA integrity and equal
loading was assessed by hybridization with a -actin cDNA
probe.
RT-PCR—Total RNA was reverse-transcribed using the
Thermoscript RT-PCR system (Invitrogen). A PCR reaction
was then performed with the followingMmp1a-specific prim-
ers: Mmp1a-exon 4, 5-GGACCTAACTATAAGCTTGCT-
CACA-3; Mmp1a-exon 7, 5-CTGGAAGATTTGGCCA-
GAGAATAC-3. The PCR reaction was performed in a
GeneAmp 9700 PCR system from Applied Biosystems for 35
cycles of denaturation (95 °C, 30 s), annealing (60 °C, 30 s), and
extension (72 °C, 1 min). As a control, -actin was PCR-ampli-
fied from all samples under the same conditions. Induction of
cancer or other pathologies inmice was performed as indicated
in the corresponding references: B16F10 and LLC lung cancer
cellmodels (23), 3-methyl-cholanthrene-induced fibrosarcoma
and 9,10-dimethyl-1,2-benzanthracene-induced skin cancer
(24), N,N-diethylnitrosamine-induced hepatocarcinoma (25),
4-nitroquinoline 1-oxide-induced oral squamous carcinoma
(26), CCl4-induced hepatic fibrosis (27), for bleomycin-induced
lung fibrosis (28), mouse mammary tumor virus-polyomamid-
dle T antigen breast cancer (29), and keratin 14-human papil-
lomavirus type 16 skin cancer (30).
Urethane Carcinogenesis Model—Mouse experimentation
was done in accordance with the guidelines of the Universidad
de Oviedo (Spain), regarding the care and use of laboratory
animals. For urethane (ethylcarbamate; Sigma) chemical carci-
nogenesis, 12-week-old mice (15 animals per group) were
Mmp1aDeficiency Protects against Lung Carcinoma
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injected intraperitoneally with two doses (separated by 48 h) of
a freshly prepared solution of 1 mg of urethane/g of body
weight, dissolved in sterile 0.9% NaCl (saline). Mice were sacri-
ficed 32 weeks after urethane exposure, and their lungs were
either snap-frozen in liquid nitrogen for further RNA and pro-
tein analysis or fixed in 4% paraformaldehyde and processed for
histological studies. Paraffin-embedded samples were cut in
serial sections, stained with hematoxylin and eosin, and exam-
ined by two experienced pathologists without previous knowl-
edge of mice genotypes. The total number of cells for each
tumor was estimated from the number of cells present in the
area of maximal section and tumors were then classified as
small ( 103 cells) and large (	103 cells).
Difference Gel Electrophoresis—Lungs from WT and KO
mice obtained 32 weeks after urethane injection were rinsed in
TAM (10 mM Tris, pH 8.5, 5 mM magnesium acetate) and
homogenized in TUCT (2 M thiourea, 7 M urea, 4% CHAPS, 30
mM Tris, pH 8.5). 50 g of each sample were labeled with 400
pmol of a specific fluorophore (GE Healthcare): CyDye 3 (WT
sample), CyDye 5 (KO sample), and CyDye 2 (pool of WT and
KO sample, 1:1). Labeled samples were combined, and UCDA
(8 M urea, 4% CHAPS, 130 mM DTT, 2% IEF buffer) was added
in a 1:1 ratio. UCDA (8 M urea, 4%CHAPS, 13mMDTT, 1% IEF
buffer) was used to reach 450 l of final volume. Samples were
loaded in a strip holder, and 24-cm IPG strips, nonlinear pH
gradient 3–11 (GE Healthcare), were placed over them. After
strip rehydration, protein isoelectrofocusing was allowed to
proceed for 26 h on an IPGphor Unit (GE Healthcare) in the
dark at 18 °C. Then, strips were equilibrated for 15 min in SES-
DTT (6 M urea, 30% glycerol, 2% SDS, 75 mM Tris, pH 6.8, 0.5%
DTT, and bromphenol blue) and 15 min in SES-IA (SES with
4.5% iodoacetamide), mounted on top of a 13% SDS-PAGE and
electrophoresed at 80 V overnight in the dark at 18 °C. After
SDS-PAGE, cyanine dye-labeled proteins were visualized
directly by scanning using a TyphoonTM 9400 imager (GE
Healthcare) and analyzed with Progenesis SameSpots software
(Nonlinear Dynamics) and stained with SYPRO Ruby (Molec-
ular Probes).
Tryptic Digestion and MALDI-TOF Analysis—Differential
spots weremanually excised over a transilluminator. Gel pieces
were washed twice with 25 mM ammonium bicarbonate/aceto-
nitrile (70:30), dried for 15 min at 90 °C, and incubated with 12
ng/l trypsin (Promega) in 25 mM ammonium bicarbonate for
1 h at 60 °C. Peptides were purifiedwith ZipTipC18 (Millipore)
and eluted with 1 l of -cyano-4-hydroxycinnamic acid to be
placed onto a MALDI-TOF plate. Once dried, they were ana-
lyzed bymass spectrometry on a time-of-flight mass spectrom-
eter equipped with a nitrogen laser source (Voyager-DE STR,
Applied Biosystems). Data from 200 laser shots were collected
and analyzed with Data Explorer (version 4.0.0.0, Applied
Biosystems).
Western Blotting—Samples were electrophoresed and trans-
ferred to PVDF (0.45-m pore size) membranes (Millipore).
Blots were blockedwith 5% nonfat drymilk in TBS-T buffer (20
mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.05% Tween 20) for
1 h at room temperature and incubated overnight at 4 °C with
3%BSA inTBS-Twith either 0.2g/ml anti-CHI3L3, 0.2g/ml
anti-S100A8 (R&D Systems), and 1:1000 anti-receptor for
advanced glycation end-products (RAGE) (Cell Signaling).
Finally, the blots were incubated for 1 h at room temperature in
2.5% nonfat dry milk in TBS-T buffer with 10 ng/ml of goat
anti-rat horseradish peroxidase (GE Healthcare), rabbit anti-
goat (Thermo Scientific), and donkey anti-rabbit (GE Health-
care), respectively. Then, blots were washed with TBS-T and
developed with Immobilon Western chemiluminescent HRP
substrate (Millipore). Chemiluminescent images were taken
with a Fujifilm LAS3000 mini apparatus.
Enzymatic Assays—For in vitro proteolysis assays, we used
recombinant S100A8 and S100A9 kindly provided by Dr.
Philippe Tessier and recombinant CHI3L3 and MMP-1 from
R&D Systems. Briefly, 100 ng of rat MMP-1 per reaction was
activated with 4-aminophenylmercuric acetate at 37 °C for 2 h.
Then, purified CHI3L3, S100A8, and S100A9 (1g) were incu-
bated with activated MMP-1 at 37 °C for 24 h and analyzed by
SDS-PAGE and Western blot.
Analysis of Cytokine Levels—To evaluate the levels of differ-
ent Th1/Th2 cytokines, we used amouse Th1/Th2/Th17/Th22
13plex FlowCytomix Multiplex kit and a TGF-1 kit (eBiosci-
ence), following the manufacturer’s instructions. Briefly, snap-
frozen lungs were homogenized at 4 °C in T-PER containing
Complete Mini Protease Inhibitor Mixture tablets (1 tablet/50
ml of T-PER stock reagent) and centrifuged at 9,000 g for 15
min. Total protein concentration in supernatant was deter-
mined using a BCA kit (Pierce). A total of 100g of each homo-
genate was incubated with antibody-coated bead complexes
and biotinylated secondary antibody for 2 h. After washing, 100
l streptavidin-phycoerythrin was added to eachwell and incu-
bated for 1 h. Samples were then transferred to appropriate
cytometry tubes and analyzed using the FC500Cellular Cytom-
ics analyzer (Beckman Coulter). A minimum of 300 events
(beads) were collected for each cytokine/sample, and median
fluorescence intensities were obtained. Cytokine concentra-
tions were calculated based on standard curve data using Flow-
Cytomix Pro software (version 3.0, eBioscience). The results
were expressed as mean
 S.E. (n 5).
RESULTS
GenerationandPhenotypeAnalysis ofMmp1a-deficientMice—
To analyze the in vivo role in cancer of Mmp-1a, the murine
counterpart of humanMMP-1, we generatedmutantmice defi-
cient in Mmp1a by replacing exons 4, 5, and 6 encoding the
catalytic domain, with a PGK-neomycin cassette (Fig. 1A). Fol-
lowing heterozygote intercrossing,Mmp1a-null, heterozygous,
and wild-type mice were obtained in the expected Mendelian
ratios. We verified homozygosity with respect to the mutated
allele by Southern blot and the absence of functional transcripts
by Northern blot analysis of placenta, a positive control for
expression of this gene (Fig. 1, B and C). Despite the Mmp1a
deficiency, these mutant mice developed normally and were
fertile, and their long term survival rates were indistinguishable
from those of their wild-type littermates. Furthermore, histo-
pathological analysis of multiple tissues fromMmp1a/ adult
animals did not reveal any differences with wild-type tissues
(data not shown). Taken together, these results demonstrate
thatMmp-1a is absolutely dispensable for embryonic and adult
mouse development as well as for normal growth and fertility.
Mmp1aDeficiency Protects against Lung Carcinoma
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Analysis of Cancer Susceptibility of Mmp1a-deficient Mice—
The dispensability ofMmp-1a formouse development, growth,
and fertility opened the possibility to perform long term studies
aimed at analyzing cancer susceptibility inmice deficient in this
metalloproteinase. For this purpose, and because previous
results had suggested that the expression of mouse Mmp1a in
normal and pathological conditions could be more restricted
than that of humanMMP1 (22), we first performed an RT-PCR
expression analysis ofMmp1a in samples from wild-type mice
in which cancer and other pathologies had been induced. As
can be seen in Fig. 2A,Mmp1a expression was clearly detected
in samples from lung carcinomas induced by chemical carcin-
ogens or by Lewis cancer cells, in skin tumors induced by 9,10-
dimethyl-1,2-benzanthracene/TPA or 3-methyl-cholanthrene,
in oral carcinomas induced by 4-nitroquinoline 1-oxide, and in
some acute pulmonary lesions induced by bleomycin treat-
ment. In contrast, no significant expression of this mouse met-
alloproteinase gene was detected in mammary tumors induced
by mouse mammary tumor virus-polyomamiddle T antigen or
in their metastasis (Fig. 2A). According to these results, we
focused our study on the analysis of the susceptibility of
Mmp1amutant mice to lung cancer.
To this end,Mmp1a/mice and their wild-type littermates
were subjected to a chemical carcinogenesis protocol with ure-
thane and, after 8 months, mice were sacrificed, and the num-
ber and histopathological characteristics of their pulmonary
lesions were examined. The penetrance of this carcinogenesis
model was 100%, and all mice developed tumors. Nevertheless,
as can be seen in Fig. 2, B andC, the number of lung tumors per
mouse was higher in wild-type than in mutant mice, especially
in the case ofmalemice, a gender difference that we had already
observed in our previous studies withMmp8mutant mice (24).
Nevertheless, and beyond these sex-specific differences, we can
conclude that the loss of Mmp-1a protects against lung cancer
induced by chemical carcinogens such as urethane. To attempt
to extend these observations, we next performed a histopatho-
logical analysis of tumors generated in both genetic back-
grounds with the finding that the number of Mmp1a mutant
mice that developed large tumors was notably lower than that
of wild-type mice (Fig. 3A). Likewise, we could observe the
presence of many inflammatory infiltrate foci in the lungs of
knock-out mice (Fig. 3B). Further analysis revealed that the
inflammatory infiltrate present inMmp1a/mice wasmainly
constituted bymature lymphocytes.We also evaluated the pos-
sibility that this inflammatory response was secondary to bron-
chial damage caused by the lung carcinomas,which could result
in obstructive pneumonia with intra-alveolar macrophages.
However, we did not find any evidence in this regard. These
characteristics are fully consistent with the idea that the
absence of Mmp-1a hampers tumor progression.
Proteomic Analysis of Lung Tissues from Mmp1a-deficient
Mice—As a first step to elucidate the molecular mechanisms
underlying the above described tumor-promoting properties of
Mmp-1a, we performed a proteomic analysis by difference gel
electrophoresis of lung samples from urethane-treated mutant
mice and the corresponding controls. After these difference gel
FIGURE 1. Targeted disruption of mouseMmp1a gene. A, restriction maps of theMmp1a gene region of interest (top), the targeting construct (center), and
the mutant locus after homologous recombination (bottom). B, EcoRI Southern blot analysis ofMmp1a/,Mmp1a/, andMmp1a/mice. C, detection of
Mmp1amRNA in placenta by Northern blot analysis.
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electrophoresis experiments coupled to mass-spectrometry
analysis, we could identify a series of differential proteins
between tissues from normal and mutant mice (supplemental
Table 1). Specifically, we focused on chitinase-3-like protein 3
(CHI3L3) andRAGE,whichwere up-regulated inwild-type and
knock-out mice, respectively (Fig. 4A and supplemental Fig. 1A).
To further validate these results, we performed two-dimen-
sionalWestern blot analysis with antibodies specific against the
differential proteins identified by difference gel electrophoresis
in the urethane-treated mice lungs (supplemental Fig. 1B).
These analyses, together with those performed with other ure-
thane-treated littermates, corroborated that both CHI3L3 and
RAGE protein levels were increased in lung samples fromwild-
type andMmp1a/mice, respectively (Fig. 4B). Additionally,
we observed that CHI3L3was the target of a processing event in
the urethane-treated lung samples from wild-type that was not
present in the equivalent samples from Mmp1a/ mice (Fig.
4B). By using mass spectrometry analysis, we identified these
different forms ofCHI3L3 as the complete protein or fragments
thereof corresponding to theN-terminal andC-terminal region
(supplemental Fig. 1A).We next evaluated the possibility that
levels of the S100A8 and S100A9 ligands of the RAGE receptor
could also be altered in the lung samples from knock-out mice.
To this purpose, we performed a bidimensional Western blot
analysis, which demonstrated the accumulation of high levels of
S100A8, as well as the occurrence of a differential processing
event of this chemotactic protein in samples fromMmp1a/
mice (Fig. 4C). By contrast, S100A9 levels did not exhibit any
significant difference in mice from both genotypes (data not
shown). To investigate whether any of these proteins could be a
substrate for MMP-1, we performed an in vitro digestion with
the recombinant protease. As can be seen in Fig. 4D, incubation
with recombinant MMP-1 caused a shift in the electrophoretic
mobility of the large form of S100A8, similar to that produced
by MMP-2, used as a control on the basis of its previously
described cleavage of this protein (31). By contrast, S100A9 and
CHI3L3 were not cleaved by this collagenolytic enzyme (Fig.
4D). Taken together, these results could indicate the occur-
rence of an imbalance in the inflammatory response induced in
wild-type andMmp1a/mice by chemical carcinogens.
Inflammatory Response Evaluation after Urethane-lung
Carcinogenesis—Because the high levels of CHI3L3 in wild-
type mice could be indicative of a Th2 protumoral inflamma-
tory response (32, 33), and the increased levels of RAGE and its
ligand S100A8 inmutant mice could point to the occurrence of
a Th1 anti-tumoral response (33, 34), we next evaluated the
levels of Th1 and Th2 cytokines in lungs from wild-type and
Mmp1a knock-out mice. To this aim, a total of 14 different
FIGURE 2.Mmp1a relevance on cancer susceptibility inmice. A, mRNA expression levels in tissues fromwild-typemice subjected to different experimental
protocols. MMTV-PyMT, mouse mammary tumor virus-polyoma middle T antigen; K14-HPV16, keratin 14-human papillomavirus type 16; MCA, 3-methyl-
cholanthrene;DMBA, 9,10-dimethyl-1,2-benzanthracene.DEN,N,N-diethylnitrosamine; 4-NQO, 4-nitroquinoline 1-oxide; CCl4, carbon tetrachloride. B, number
of total lung tumors permouse after 8months of urethane intraperitoneal treatment. C, representative images of lungs frommutant and control mice (n 15
per group; ***, p 0.001 by Student’s t test.
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mouse cytokines were simultaneously analyzed by flow cytom-
etry. As can be seen in Fig. 5A, levels of well established Th1-
associated cytokines such as IL-1, IL-2, IL-27, and IFN-, are
increased in lungs fromMmp1a/mice compared with their
corresponding controls. Likewise, levels of IL-5, IL-10, IL-13,
and TGF-1, which are archetypal Th2-response cytokines, are
consistently higher in wild-type mice than inMmp1a-deficient
mice, although the differences did not reach statistical signifi-
cance due to high variability in the control samples. Notably,
TNF levels were not different in mice from both genotypes,
thus indicating that this cytokine is not especially relevant in
the generation ofTh1/Th2 balance differences in this particular
mouse model. Furthermore, and because IL-17 has been
described to be highly dependent on IFN- (35), we evaluated
the levels of both cytokines at different time points during the
development of the urethane-induced lung cancermodels, with
the finding that IL-17 and IFN- showed a parallel increase in
Mmp1a/ mice in the course of the carcinogenesis experi-
ment (Fig. 5B).
To further evaluate the putativeTh1-polarized inflammatory
response occurring in Mmp1a/ mutant mice during ure-
thane carcinogenesis, we analyzed levels of most significant
cytokines found at increased levels in lung fromMmp1a knock-
out mice. Thus, we measured IL-17, IL-27, and IFN- levels in
the lungs from two different groups of mutant mice based on
the lung inflammatory phenotype presented by them. To this
end, we compared mutant mice showing a high number of
inflammatory infiltrate foci in the lungs with those animals that
did not present any of these foci. It is noteworthy that the group
of mutant mice with lower number of inflammatory infiltrates
presented the higher number of tumors (mean, 8 versus 3.8,
respectively). Interestingly, the levels of these Th1-related cyto-
kines displayed by the group with inflammatory infiltrate were
higher than those found in the group inwhich that infiltratewas
not observed (Fig. 5C). Taken together, all of these results, it
seems that Mmp1a/ mice develop a Th1 antitumoral
response, which, in turn would contribute to explain the signif-
icantly low number of chemically induced lung carcinomas
observed in mice deficient in this metalloproteinase.
DISCUSSION
In this work, we have generated mutant mice deficient in
Mmp1a and demonstrated that they represent a new and valu-
able in vivomodel for the functional analysis of MMP-1 in can-
cer. During the past few years, evidence has accumulated that
MMP-1 is associated with tumor progression and metastasis
(16, 17, 19). However, and somewhat surprisingly, very limited
information is available about the putative functions mediated
byMMP-1 during cancer development and progression. This is
especially puzzling if we consider that MMP-1 was the first
human MMP cloned and characterized at the biochemical
level, and its correlative links with tumor invasion and metas-
tasis were first reported more than 20 years ago (11, 36). One
possibility to explain this lack of functional information about
MMP-1 in cancer is the absence of an in vivomodel of MMP-1
deficiency, an aspect that has been largely attributed to thewide
assumption that no MMP-1 ortholog was present in rodents.
However, our finding of two murine genes (Mmp1a and
Mmp1b, also known as McolA and McolB) similar to human
MMP-1 opened a series of further studies, which allowed us to
conclude that Mmp1a is a bona fide counterpart of human
MMP-1 (22). This finding was the starting point of a long term
work that has now led us to the generation and analysis of
mutant mice deficient inMmp1a.
Similar to most cases of Mmp deficiency (1), Mmp1a/
mice are viable and fertile. The absence of alterations in
Mmp1a-null mice in processes such as uterine involution or
mammary gland involution are absolutely consistent with pre-
vious findings demonstrating that functions originally ascribed
toMMP-1were in fact performed by other collagenases such as
MMP-8 and MMP-13 (37–39). The current work describing
the generation of the first in vivomodel to differentially evalu-
ate both collagenases may contribute to clarifying their relative
importance in different biological processes. Notably, the lack
of significant abnormalities inMmp1a/mice has facilitated
studies aimed at evaluating their cancer susceptibility. These
studies first focused on lung carcinomas because our previous
Mmp1a expression analysis in tissues from mice subjected to
several carcinogenesis protocols revealed high expression levels
of this murine metalloproteinase in different samples of lung
cancer. After application of a urethane-based protocol of lung
FIGURE 3. Phenotypic features of urethane-induced tumors in Mmp1a
wild-type and knock-outmice. A, graphic representation of size tumor inci-
dence in males. Knock-out mice show a lower incidence of large tumors
(	103 cells). B, inflammatory infiltrate incidence in both sexes. We represent
the number of mice which present inflammatory infiltrate foci in their lungs,
showing an increased presence of inflammatory foci in lungs from knock-out
mice. Inflammatory infiltrates are indicated with arrows, and tumors are
shown with arrowheads.
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FIGURE 4. A, difference gel electrophoresis analysis of lung tissue fromurethane-treatedmice. Overlaying green and red image highlights differences between
wild-type and Mmp1a/ mice. Yellow indicates no change, red spots indicate more abundance in knock-out mice, and green spots more abundance in
wild-typemice. Selected proteins are labeledwithwhite circles, and bidimensional validation analysis is shown in supplemental Fig. 1. All differential analyzed
spots are listed in supplemental Table1.B,Westernblot analysis extended tootherurethane-treated littermates showing the increasedCHI3L3andRAGE levels
in wild-type and knock-out mice, respectively, as well as the differential processing of CHI3L3 in wild-type lungs no present in the mutant lungs. Load
control is shown at the bottom of each panel. C, Western blot analysis of the RAGE ligand S100A8 showing accumulation of different isoforms of this
chemokine in lung from knock-outmice.D, in vitro cleavage assays with humanMMP-1. Purified S100A8, S100A9, and CHI3L3 (1g) were incubatedwith
100 ng of activated MMP-1, which resulted in specific cleavage of S100A8 (*), but not S100A9 and CHI3L3. Recombinant MMP-2 was used as a positive
control of S100A8 cleavage.
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cancer induction, we observed thatMmp1a/mice showed a
lower incidence of lung carcinomas than their corresponding
wild-type littermates. Interestingly, this difference was more
marked in male than in female mutant mice, indicating the
occurrence of a gender difference that has been previously
reported in other models ofMmp deficiency (24). The different
susceptibility of male and female Mmp1a/ mice to tumor
development is likely due to hormonal factors as previously
demonstrated in theMmp8-null model, in which ovariectomy
or estrogen receptor antagonist treatment increases the inci-
dence of chemically induced tumors inMmp8/ female mice,
and abrogates the gender differences in cancer susceptibility
(22). Similar studies in Mmp1a-null mice will be necessary to
confirm the hormonal basis of the gender differences in cancer
susceptibility in these mutant animals. Interestingly, histo-
pathological analysis showed that tumors generated in
Mmp1a/ mice are smaller than those of wild-type mice, a
characteristic which is consistent with the idea that the absence
of Mmp-1a hampers tumor progression. These in vivo findings
agree perfectly with very recent in vitro data showing that
silencing Mmp1a suppresses invasive growth of lung cancer
cells in three-dimensional matrices, whereas ectopic expres-
sion of this murine metalloproteinase confers invasive proper-
ties to epithelial cells (40).
The protumorigenic role ofMMPs was originally ascribed to
their ability to break down tissue barriers formetastatic spread.
Both human MMP-1 and mouse Mmp-1a are potent collage-
nases with the ability to degrade different types of fibrillar col-
lagens consistent with a role for these metalloproteinases
degrading the extracellular matrix and promoting tumor pro-
gression (16, 17, 19). Nevertheless, the growing evidence that
virtually all MMPs, including MMP-1, target many other pro-
teins distinct from extracellular matrix components (41–43),
prompted us to perform comparative proteomic studies
between samples of Mmp1a mutant and wild-type mice to try
to identify putative in vivo substrates of Mmp-1a. Among the
identified alterations, we found decreased CHI3L3 levels and
increased RAGE levels in lung samples from urethane-treated
mutant mice compared with controls. Further studies demon-
strated that the S100A8 ligand for the RAGE receptor is also
elevated in samples from Mmp1a mutant mice. Accordingly,
this chemotactic protein could be a substrate directly targeted
FIGURE 5.Analysis of cytokine levels in lung fromMmp1awild-typeandknock-outmice treatedwithurethane.A, cytokine levelsmeasured in lungmice
after 8months of urethane intraperitoneal treatment. B, measurement of IFN- and IL-17 in the lungs of mutant and control mice at several time points along
the urethane carcinogenesis model. C, levels of Th1 cytokines in lungs from two different groups of Mmp1a-deficient mice separated on the basis of their
inflammatory phenotype.Mmp1a/ group A (Mmp1a / A) represents thosemutant mice showing a notably high number of inflammatory infiltrate foci in
the lungs, whereas Mmp1a/ group B (Mmp1a/ B) represents those mutant mice with no overt infiltrate foci in their lungs. *, p 0.01; **, p 0.001 by
Student’s t test.
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byMmp1a, a proposal that we further assessed by performing a
series of enzymatic assays, which demonstrated that the recom-
binant collagenase cleaves S100A8, but no other related pro-
teins such as S100A9. The impaired degradation of this immu-
noregulatory protein in Mmp1a-deficient mice could also
contribute to the generation of marked differences in the
inflammatory response induced by chemical carcinogens in
Mmp1a wild-type and mutant mice. Thus, the increased levels
of CHI3L3 together with high levels of several Th2-related
cytokines in wild-type mice strongly suggests that urethane is
inducing the archetypical Th2-polarized inflammatory
responsewhich operates under protumoral stimuli (44). In con-
trast, the absence of increased levels of CHI3L3 inMmp1a/
mice together with the presence of high levels of RAGE and its
ligand S100A8, which are Th1 markers (33, 34), as well as high
levels of IFN- and other antitumor cytokines such IL-1 and
IL-2, is consistent with the possibility that Mmp1a deficiency
hampers the Th2 response triggered by carcinogen injection in
Mmp1a/mice. Moreover, further studies showed that mice
that developed higher number of lung tumors did not display
theTh1 cytokine profile observed in theirmutant counterparts.
Thus, it is tempting to speculate that inflammatory infiltrate in
knock-out mice confers antitumor properties that finally result
in the observed lower number of lesions in this group of ani-
mals. Likewise, our data are consistent with the hypothesis that
IL-17 acts as a tumor-inhibiting cytokine in the lung carcino-
genesis model used in this work.
MMPs have been associated with inflammatory responses in
a wide variety of diseases (45). Likewise, several reports have
described that cytokines released from different Th1/Th2 cell
types can modulate MMP expression. Thus, it is well estab-
lished that Th2 responses are associated with an increased
expression of matrix degradative MMPs, including human
MMP-1 (46). Moreover, MMPs may also act as direct inducers
of this process, modulating chemokine gradients or processing
specific cytokines, and finally switching the balance between
both types of responses. This is the case of MMP-2, which is
overexpressed in multiple cancers and induces a Th2 polariza-
tion through the degradation of type I IFN receptor in dendritic
cells (47). In addition, MMP-9 proteolytically activates TFG-,
which in turn promotes differentiation toward the Th2 protu-
morigenic phenotype (48). Accordingly, lungs from Mmp1a-
deficient mice exhibit lower levels of active TFG-1 than con-
trols suggesting that these mutant mice lack the capacity to
proteolytically activate TFG-1. Finally, the fact that human
MMP-1 also cleaves the latent form of TGF- and facilitates
tumor invasion and angiogenesis (42) would agree very well
with our proposal that its mouse ortholog Mmp-1a acts in vivo
as a switching protease, which changes the Th1/Th2 balance
toward a protumoral state. Nevertheless, further experimental
work, now in progress, will be required to better understand the
molecular mechanisms underlying this Mmp1a-mediated
inflammatory response to chemical carcinogens.
In summary, the generation of the first mouse model of
MMP-1 deficiency has contributed to the in vivo validation of
this enzyme as a protumorigenic proteasewith potential impact
in different stages of tumor progression, including cell prolifer-
ation and regulation of inflammatory responses. These studies
have also validated the concept that human MMP-1 is a target
protease, at least in some types of cancer, in which its expres-
sion is profoundly deregulated. Additional studies aimed at
inducing other tumor types inMmp1a/ mice will be neces-
sary to define the precise in vivo role of this protease in different
malignancies because it could have dual roles in tumor devel-
opment (49). Likewise, studies involving mice simultaneously
deficient in Mmp1a and other protumorigenic MMPs will be
required to evaluate the functional redundancy and relative rel-
evance of MMP-1 in different stages of cancer progression.
Hopefully, these studies will contribute to the appropriate tar-
geting of this proteolytic enzyme as part of novel and combined
targets for the treatment of malignant tumors (50).
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Supplementary Figure 1.Validation of selected proteomic alterations. (A) DiGE selected CHI3L3 and RAGE spot proteins of lung
tissues from urethane-treated wild-type (green) and knock-out (red) mice (B) Bi-dimensional Western-blot analysis with anti-
Supplementary Fig. 1. Fanjul-Fernandez et al
.
CHI3L3 and anti-RAGE specific antibodies of the lung urethane-treated mice confirming the increased protein levels of these
proteins in the lungs of Mmp1a+/+ (green) and Mmp1a-/- (red) mice, respectively.
Name SwissProt name kDa pI Hits % sequence coverage Slope (ppm)
SupplementaryTable 1. Differential proteins in urethane-treated lungs of Mmp1a+/+ (green) and Mmp1a-/- (red) mice, 
identified by DiGE analysis. 
Actin, cytoplasmic 1 ACTB_MOUSE 41.606 5.29 10 33 7
Actin, cytoplasmic 1 ACTB_MOUSE 41.606 5.29 7 26 19
Actin, cytoplasmic 2 ACTG_MOUSE 41.662 5.3 4 14 -29
Advanced glycosylation end product-specific product RAGE_MOUSE 41.768 6.4 6 28 -20
Alpha-2-macroglobulin 35 kDa subunit A2M_MOUSE 28.226 7.08 10 40 -6
Carbonyl reductase [NADPH]2 CBR2 MOUSE 25 958 9 09 6 15 22  _ . .
Chitinase-3 like protein 3 (101-384) CH3L3_MOUSE 42.322 5.33 5 15 26
Chitinase-3 like protein 3 (117-384) CH3L3_MOUSE 42.322 5.33 5 13 10
Chitinase-3 like protein 3 (165-384) CH3L3_MOUSE 42.322 5.33 7 26 -6
Chitinase-3 like protein 3 (178-384) CH3L3_MOUSE 42.322 5.33 6 22 -2
Chitinase-3 like protein 3 (76-160) CH3L3_MOUSE 42.322 5.33 6 18 26
Chitinase-3 like protein 3 (76-160) CH3L3_MOUSE 42.322 5.33 4 11 -13
Chitinase-3 like protein 3 (92-278) CH3L3_MOUSE 42.322 5.33 5 16 -20
Complement C1q tumor necrosis factor-related protein 4 C1QT4_MOUSE 33.387 9.18 5 22 43
Cytochrome c oxidase subunit 5B, mitochondrial COX5B_MOUSE 10.718 5.74 5 58 -2
Dihydropyrimidase-related protein 2 DPYL2_MOUSE 62.278 5.95 19 41 23
Fatty acid-binding protein,epidermal FABP5 MOUSE 15.006 6.19 4 27 32_
Glutathione S-transferase A3 GSTA3_MOUSE 25.229 8.77 4 15 0
Heat shock protein beta-1 HSPB1_MOUSE 23.014 6.11 5 30 -30
Hemoglobin subunit beta-1 HBB1_MOUSE 15.709 7.26 8 66 26
Kelch-like protein 9 KLHL9_MOUSE 69.400 6.00 5 7 -27
L-lactate dehydrogenase B chain LDHB_MOUSE 36.441 5.7 8 25 29
Macrophage capping protein CAPG MOUSE 39 241 6 73 6 18 13-  _ . .
Myosin light chain 4 MYL4_MOUSE 21.028 4.96 6 33 -6
Myosin regulatory light chain 2, atrial isoform MLRA_MOUSE 19.450 4.75 8 50 -9
Nuclease-sensitive element-binding protein-1 YBOX_MOUSE 35.599 9.88 4 11 16
Peroxiredoxin 1 PRDX1_MOUSE 22.177 8.26 7 33 2
Peroxiredoxin 6 PRDX6_MOUSE 24.740 5.71 11 51 10
Peroxiredoxin 6 PRDX6_MOUSE 24.740 5.71 5 25 29
Peroxiredoxin 6 PRDX6_MOUSE 24.740 5.71 8 38 -13
Phosphoglycerate mutase-1 PGAM1_MOUSE 28.701 6.75 2 11 16
Protein disulfide-isomerase A3 PDIA3_MOUSE 54.268 5.69 16 38 16
S100-A6 S10A6_MOUSE 10.051 5.30 2 17 15
Serpin A12 SPA12 MOUSE 45 490 9 14 6 14 26 _ . .
Thimet oligopeptidase THOP1_MOUSE 77.895 5.71 3 4 16
Tropomyosin alpha-3 chain TPM3_MOUSE 32.863 4.67 14 32 -26
Supplementary Table 1 .     Fanjul‐Fernandez et al.
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